Checking the Benefits of Fecal Transplant for Cancer Treatment Side Effects
NCT04038619 · RecruitingThis trial looks at how well fecal microbiota transplantation (FMT) helps treat diarrhea and colitis caused by certain cancer medicines called immune-checkpoint inhibitors. It focuses on patients with genitourinary cancers. The main goal is to see if FMT can reduce these side effects effectively and safely.
Locations and contact
This trial is running at 1 location in the United States. It is currently recruiting.
United States1 location · 1 recruiting
- M D Anderson Cancer CenterHouston, TexasRecruiting
Who can join
Adults aged 18 and older can join. This trial is for people diagnosed with specific cancers who have new diarrhea or colitis from certain cancer medicines. Those with active infections or certain health conditions cannot participate. The trial team will confirm if each person is eligible.
What happens during the trial
Participants will take a medicine called loperamide and then have fecal microbiota transplantation through a colonoscopy. Everyone in the trial receives this treatment, and there are no random groups. They will be monitored for 2, 4, and 8 weeks, and again at 3 months after treatment.
The trial team
The trial is run by M.D. Anderson Cancer Center, with support from the National Cancer Institute. Dr. Yinghong Wang is the principal investigator leading the study.
Important dates
The trial started on February 1, 2021, and is currently enrolling new participants. It is expected to finish by December 31, 2027.
Additional information
This is a Phase 1 trial, meaning it is looking at how safe and effective the treatment is. It is FDA-regulated and aims to include about 40 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →